Related Experiment Video

Updated: Jun 17, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

Dissecting the role of mTOR: lessons from mTOR inhibitors

Ryan J O Dowling1, Ivan Topisirovic, Bruno D Fonseca

  • 1Department of Biochemistry, Rosalind and Morris Goodman Cancer Centre, McGill University, 1160 Pine Avenue West, Rm. 609, Montreal, Quebec, Canada H3A 1A3.

Biochimica Et Biophysica Acta
|December 17, 2009
PubMed

Insights

The target of rapamycin (TOR) pathway is crucial for cell growth and is often hyperactivated in cancers. New drugs targeting the mTOR kinase directly offer potential advantages over existing rapamycin treatments for cancer therapy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • The serine/threonine kinase target of rapamycin (TOR) pathway regulates fundamental cellular processes like survival, growth, and proliferation.
  • Hyperactivation of the mTOR pathway is implicated in various human malignancies, making it a key target for anti-cancer drug development.

Purpose of the Study:

  • To review the current understanding of the mTOR signaling pathway.
  • To discuss the molecular mechanisms of rapamycin and novel active-site mTOR inhibitors.
  • To evaluate the potential benefits and limitations of these drugs in cancer treatment.

Main Methods:

  • Literature review of mTOR signaling and inhibitor mechanisms.
  • Analysis of rapamycin and novel active-site mTOR inhibitor actions.
  • Discussion of clinical applications and challenges in cancer therapy.

Main Results:

  • Rapamycin and its analogs (rapalogs) allosterically inhibit mTORC1 but do not affect all mTOR functions.
  • Novel active-site inhibitors targeting mTOR kinase activity, inhibiting both mTORC1 and mTORC2, have been developed.
  • Understanding the precise mechanisms of mTOR inhibition is crucial for optimizing cancer therapy.

Conclusions:

  • mTOR pathway dysregulation is a significant factor in cancer development.
  • While rapamycin is used clinically, its limitations necessitate the development of more comprehensive inhibitors.
  • Directly targeting mTOR kinase activity with novel inhibitors shows promise for improved cancer treatment strategies.

More Related Videos

Polysome Fractionation and Analysis of Mammalian Translatomes on a Genome-wide Scale10:56

Polysome Fractionation and Analysis of Mammalian Translatomes on a Genome-wide Scale

Published on: May 17, 2014

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation09:37

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation

Published on: March 15, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...